Loading provider…
Loading provider…
Hematology & Oncology Physician in Chicago, IL
NPI: 1114089661Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Richard's Phone Numberphone_androidMobile
Get Richard's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
1978 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Stanford University School Of Medicine
med.stanford.edu
Medical School
Until 1977
University of Chicago
Fellowship • Hematology and Medical Oncology
1980 - 1983
Residency • Internal Medicine
1977 - 1980
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 43 | 302 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 31 | 40 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 28 | 33 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 23 | 34 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 22 | 51 |
Authors: Raimondi, S C, Dubé, I D, Valentine, M B, Mirro, J, Watt, H J, Larson, R A, Bitter, M A, Le Beau, M M, Rowley, J D
Journal: Leukemia
Authors: Jonathan Kolitz, Guido Marcucci, Nyla Heerema
Journal: J Clin Oncol
Publication Date: 2012-09-17
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Authors: John Byrd, Michael Caligiuri
Publication Date: 2004-01
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Bosutinib, DRUG: Asciminib
Lead Sponsor: Cornerstone Pharmaceuticals
Intervention / Treatment: DRUG: CPI-613 + High Dose Cytarabine and Mitoxantrone, DRUG: High Dose Cytarabine and Mitoxantrone, DRUG: Mitoxantrone, Etoposide and Cytarabine, DRUG: Fludarabine, Cytarabine, Filgrastim
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011